Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax in May had signed a deal worth at least ... were placed on the U.S. Food and Drug Administration's ability to review products. Its net loss was $81 million for the quarter ended December ...

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Novavax Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024. The low is $100 issued by Deutsche Bank on August 5 ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.